MétaCan
Menu
Back to cohort
Record W4412695719 · doi:10.1093/ejendo/lvaf148

rhPTH(1-84) for hypoparathyroidism: a randomized study of patient-reported outcomes

2025· article· en· W4412695719 on OpenAlexaff
Maria Luisa Brandi, Tamara Vokes, Natasha M. Appelman‐Dijkstra, Olulade Ayodele, Brigitte Decallonne, Renate de Jongh, Díaz Curiel M, William D. Fraser, Richard D. Finkelman, Ansgar Heck, Steven Ing, Peter Kamenický, Aliya Khan, Christopher S. Kovács, Bruno Lapauw, Graham Leese, Giovanna Mantovani, Guillermo Martínez Diaz‐Guerra, Laura Masi, Miguel Melo, Andrea Palermo, Narendra Reddy, Lars Rejnmark, Elena Tokareva, Marie‐Christine Vantyghem, Suwei Wang, Mark Warren, Brian Yan

Bibliographic record

VenueEuropean Journal of Endocrinology · 2025
Typearticle
Languageen
FieldMedicine
TopicThyroid and Parathyroid Surgery
Canadian institutionsMcMaster UniversityMemorial University of NewfoundlandMcMaster University Medical Centre
FundersNovo NordiskUltragenyx PharmaceuticalAlexion PharmaceuticalsSoft BonesTakeda Pharmaceuticals U.S.A.AmgenPfizerEli Lilly and CompanyTakeda Development Center Americas
KeywordsPlaceboMedicineClinical endpointHypoparathyroidismRandomized controlled trialInternal medicineQuality of life (healthcare)Confidence intervalUrology

Abstract

fetched live from OpenAlex

OBJECTIVE: To assess the impact of recombinant human parathyroid hormone (1-84) [rhPTH(1-84)] compared with placebo, in combination with conventional therapy with vitamin D and/or calcium supplements, on health-related quality of life (HRQoL) in patients with symptomatic chronic hypoparathyroidism (cHypoPT). DESIGN: Randomized, double-blind, placebo-controlled, phase 3b-4 study (ClinicalTrials.gov ID: NCT03324880). METHODS: Eligible patients with symptomatic cHypoPT were randomized to receive subcutaneous rhPTH(1-84) 25-100 µg/day or placebo. The primary endpoint was the change from baseline to week 26 in Hypoparathyroidism Symptom Diary (HypoPT-SD) symptom subscale score. Key secondary endpoints were changes from baseline to week 26 in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue and in 36-item Short Form Health Survey physical component summary (SF-36v2 PCS). RESULTS: In total, 93 patients were randomized to receive treatment: 45 received rhPTH(1-84) and 48 received placebo. Change from baseline to week 26 in HypoPT-SD symptom subscale score was significantly greater (improved) in the rhPTH(1-84) group than in the placebo group (difference in least-squares mean changes, -0.53; 95% confidence interval, -0.90 to -0.15, P = .003). Key secondary endpoints, changes between baseline and week 26 in the FACIT-Fatigue and SF-36v2 PCS scores were also significantly greater (improved) in the rhPTH(1-84) group than in the placebo group. The safety profile of rhPTH(1-84) was consistent with previous findings, and no new safety signals were identified. CONCLUSIONS: rhPTH(1-84) alongside conventional therapy improved symptom burden (as measured by the HypoPT-SD) and HRQoL to a greater extent than conventional therapy alone in patients with symptomatic cHypoPT.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.002
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.323
Threshold uncertainty score0.695

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0020.001
Bibliometrics0.0010.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.025
GPT teacher head0.306
Teacher spread0.281 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations4
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueEuropean Journal of EndocrinologySame topicThyroid and Parathyroid SurgeryFrench-language works237,207